Rifapentine access in Europe: growing concerns over key tuberculosis treatment component

Lorenzo Guglielmetti; Gunar Günther; Claude Leu; Liga Kuksa; Study Group on Mycobacteria of the European Society of Microbiology and Infectious Diseases (ESGMYC); European Society of Mycobacteriology (ESM); European Respiratory Society (ERS); Tuberculosis Network European Trials group (TBnet)

doi:10.1183/13993003.00388-2022

Rifapentine access in Europe: growing concerns over key tuberculosis treatment component

Lorenzo Guglielmetti (Corresponding Author)
, Gunar Günther
, Claude Leu
, Liga Kuksa
, Study Group on Mycobacteria of the European Society of Microbiology and Infectious Diseases (ESGMYC)
, European Society of Mycobacteriology (ESM)
, European Respiratory Society (ERS)
, Tuberculosis Network European Trials group (TBnet)

Rīga Stradiņš University

Research output: Contribution to journal › Letter › peer-review

33 Citations (Scopus)

Original language	English
Article number	2200388
Journal	European Respiratory Journal
Volume	59
Issue number	5
DOIs	https://doi.org/10.1183/13993003.00388-2022
Publication status	Published - 1 May 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Field of Science*

3.2 Clinical medicine
3.3 Health sciences

Publication Type*

1.1. Scientific article indexed in Web of Science and/or Scopus database

Access to Document

10.1183/13993003.00388-2022Licence: CC BY-NC

Cite this

Guglielmetti, L., Günther, G., Leu, C., Kuksa, L., Study Group on Mycobacteria of the European Society of Microbiology and Infectious Diseases (ESGMYC), European Society of Mycobacteriology (ESM), European Respiratory Society (ERS), & Tuberculosis Network European Trials group (TBnet) (2022). Rifapentine access in Europe: growing concerns over key tuberculosis treatment component. European Respiratory Journal, 59(5), Article 2200388. https://doi.org/10.1183/13993003.00388-2022

@article{843199d6cd7d4e82a20a6e4e8f39340f,

title = "Rifapentine access in Europe: growing concerns over key tuberculosis treatment component",

author = "Lorenzo Guglielmetti and Gunar G{\"u}nther and Claude Leu and Daniela Cirillo and Raquel Duarte and Garcia-Basteiro, \{Alberto L.\} and Delia Goletti and Mateja Jankovic and Liga Kuksa and Maurer, \{Florian P.\} and Fr{\'e}d{\'e}ric M{\'e}cha{\"i} and Simon Tiberi and \{Van Leth\}, Frank and Nicolas Veziris and Christoph Lange and \{Study Group on Mycobacteria of the European Society of Microbiology and Infectious Diseases (ESGMYC)\} and \{European Society of Mycobacteriology (ESM)\} and \{European Respiratory Society (ERS)\} and \{Tuberculosis Network European Trials group (TBnet)\} and Hasan Hafizi and Naira Khachatryan and Harut Aroyan and Eduard Kabasakalyan and Michael Knappik and Alena Skrahina and Dzmitry Klimuk and Alena Nikolenka and Inge Muylle and Vladimir Milanov and Desislava Velkovska and Neli Tarinska and Elizabeta Bachiyska and Despo Pieridou and Tonia Adamide and Nicos Nicolaou and Martina Vasakova and Mariia Sukholytka and Emilia Kopeck{\`a} and Beata Polakova and Anderson, \{Aase Bengard\} and Folkvardsen, \{Dorte Bek\} and Erik Svensson and Manfred Danilovits and Tiina Kummik and Tuula Vasankari and Mathilde Fr{\'e}chet-Jachym and Audrey Nahmiash and Tamar Togonidze and Zaza Avaliani and Inga Kinkladze and Rusudan Aspindzelashvili and Teona Bichashvili and Gulnazi Losaberidze and Tsitsino Merabishvili",

note = "Funding Information: Support statement: C. Lange is supported by the German Center of Infection Research (DZIF). All other authors have no funding to declare for this study. Funding information for this article has been deposited with the Crossref Funder Registry.",

year = "2022",

month = may,

day = "1",

doi = "10.1183/13993003.00388-2022",

language = "English",

volume = "59",

journal = "European Respiratory Journal",

issn = "0903-1936",

publisher = "European Respiratory Society",

number = "5",

}

Guglielmetti, L, Günther, G, Leu, C, Kuksa, L, Study Group on Mycobacteria of the European Society of Microbiology and Infectious Diseases (ESGMYC), European Society of Mycobacteriology (ESM), European Respiratory Society (ERS) & Tuberculosis Network European Trials group (TBnet) 2022, 'Rifapentine access in Europe: growing concerns over key tuberculosis treatment component', European Respiratory Journal, vol. 59, no. 5, 2200388. https://doi.org/10.1183/13993003.00388-2022

TY - JOUR

T1 - Rifapentine access in Europe

T2 - growing concerns over key tuberculosis treatment component

AU - Guglielmetti, Lorenzo

AU - Günther, Gunar

AU - Leu, Claude

AU - Cirillo, Daniela

AU - Duarte, Raquel

AU - Garcia-Basteiro, Alberto L.

AU - Goletti, Delia

AU - Jankovic, Mateja

AU - Kuksa, Liga

AU - Maurer, Florian P.

AU - Méchaï, Frédéric

AU - Tiberi, Simon

AU - Van Leth, Frank

AU - Veziris, Nicolas

AU - Lange, Christoph

AU - Study Group on Mycobacteria of the European Society of Microbiology and Infectious Diseases (ESGMYC)

AU - European Society of Mycobacteriology (ESM)

AU - European Respiratory Society (ERS)

AU - Tuberculosis Network European Trials group (TBnet)

A2 - Hafizi, Hasan

A2 - Khachatryan, Naira

A2 - Aroyan, Harut

A2 - Kabasakalyan, Eduard

A2 - Knappik, Michael

A2 - Skrahina, Alena

A2 - Klimuk, Dzmitry

A2 - Nikolenka, Alena

A2 - Muylle, Inge

A2 - Milanov, Vladimir

A2 - Velkovska, Desislava

A2 - Tarinska, Neli

A2 - Bachiyska, Elizabeta

A2 - Pieridou, Despo

A2 - Adamide, Tonia

A2 - Nicolaou, Nicos

A2 - Vasakova, Martina

A2 - Sukholytka, Mariia

A2 - Kopeckà, Emilia

A2 - Polakova, Beata

A2 - Anderson, Aase Bengard

A2 - Folkvardsen, Dorte Bek

A2 - Svensson, Erik

A2 - Danilovits, Manfred

A2 - Kummik, Tiina

A2 - Vasankari, Tuula

A2 - Fréchet-Jachym, Mathilde

A2 - Nahmiash, Audrey

A2 - Togonidze, Tamar

A2 - Avaliani, Zaza

A2 - Kinkladze, Inga

A2 - Aspindzelashvili, Rusudan

A2 - Bichashvili, Teona

A2 - Losaberidze, Gulnazi

A2 - Merabishvili, Tsitsino

N1 - Funding Information: Support statement: C. Lange is supported by the German Center of Infection Research (DZIF). All other authors have no funding to declare for this study. Funding information for this article has been deposited with the Crossref Funder Registry.

PY - 2022/5/1

Y1 - 2022/5/1

UR - https://www.scopus.com/pages/publications/85130397640

U2 - 10.1183/13993003.00388-2022

DO - 10.1183/13993003.00388-2022

M3 - Letter

C2 - 35589114

AN - SCOPUS:85130397640

SN - 0903-1936

VL - 59

JO - European Respiratory Journal

JF - European Respiratory Journal

IS - 5

M1 - 2200388

ER -

Guglielmetti L, Günther G, Leu C, Kuksa L, Study Group on Mycobacteria of the European Society of Microbiology and Infectious Diseases (ESGMYC), European Society of Mycobacteriology (ESM) et al. Rifapentine access in Europe: growing concerns over key tuberculosis treatment component. European Respiratory Journal. 2022 May 1;59(5):2200388. doi: 10.1183/13993003.00388-2022

Rifapentine access in Europe: growing concerns over key tuberculosis treatment component

UN SDGs

Field of Science*

Publication Type*

Access to Document

Other files and links

Cite this